Connor, Clark & Lunn Investment Management Ltd. Grifols Sa Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$7.71 - $11.56 $432,345 - $648,238	56,076 Added 498.36%	67,328 $778,000
Q3 2023 Nov 13, 2023	SELL	$8.91 - $10.91 $114,342 - $140,008	-12,833 Reduced 53.28%	11,252 $102,000
Q2 2023 Aug 10, 2023	BUY	$7.14 - $9.29 $61,718 - $80,302	8,644 Added 55.98%	24,085 $220,000
Q1 2023 May 09, 2023	BUY	$6.65 - $10.69 $102,682 - $165,064	15,441 New	15,441 $113,000
Q3 2022 Nov 10, 2022	BUY	$5.95 - $14.3 $178,404 - $428,771	29,984 Added 206.17%	44,527 $274,000
Q2 2022 Aug 05, 2022	SELL	$10.6 - $13.28 $217,808 - $272,877	-20,548 Reduced 58.56%	14,543 $173,000
Q1 2022 May 12, 2022	SELL	$10.37 - $12.73 $217,479 - $266,973	-20,972 Reduced 37.41%	35,091 $410,000
Q4 2021 Feb 10, 2022	BUY	$10.21 - $15.27 $572,403 - $856,082	56,063 New	56,063 $630,000
Q2 2020 Aug 13, 2020	SELL	$18.24 - $21.45 $266,304 - $313,170	-14,600 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$16.28 - $25.63 $237,688 - $374,198	14,600 New	14,600 $294,000

Others Institutions Holding GRFS

# of Institutions

164

Shares Held

140M

Call Options Held

288K

Put Options Held

389K

Capital World Investors Los Angeles, CA

21M
Shares

$165 Million
0.03% of portfolio
Brandes Investment Partners, LP La Jolla, CA

19.9M
Shares

$156 Million
2.11% of portfolio
Permian Investment Partners, LP New York, NY

12.3M
Shares

$96.8 Million
16.06% of portfolio
Black Creek Investment Management Inc. Toronto, A6

11.1M
Shares

$87.2 Million
3.5% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

10.7M
Shares

$84.2 Million
0.05% of portfolio

View Full List

About Grifols SA

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.33B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

More about GRFS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account